Tanya Stoyanova*
/in /by SOFIA
Affiliations
Associate Professor, Molecular and Medical Pharmacology
Research Interests
Stoyanova lab develops new cancer early detection approaches and therapeutic strategies for late stage cancers. The current research areas of interest are:
1) Targeted cancer therapies. Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers, including discovery and testing new therapeutic targets and new small molecule inhibitors.
2) Antibody-based therapies for advanced prostate and other metastatic epithelial cancers. Stoyanova lab develops and tests antibody-based strategies as targeted cancer therapies.
3) Combination therapies for metastatic cancers. We are testing multiple experimental agents in combination with FDA-approved cancer therapies to enhance therapeutic responses.
Publications
A selected list of publications:
Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models. Invest Radiol. 2022 Dec 22. Wu WE, Chang E, Jin L, Liu S, Huang CH, Kamal R, Liang T, Aissaoui NM, Theruvath AJ, Pisani L, Moseley M, Stoyanova T, Paulmurugan R, Huang J, Mitchell DA, Daldrup-Link HE. PMID: 36729074.
Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022 Oct; 238:108255. Alabi BR, Liu S, Stoyanova T. PMID: 35905791.
Acoustic Fabrication of Living Cardiomyocyte-based Hybrid Biorobots. ACS Nano. 2022 Jul 26; 16(7):10219-10230. Wang J, Soto F, Ma P, Ahmed R, Yang H, Chen S, Wang J, Liu C, Akin D, Fu K, Cao X, Chen P, Hsu EC, Soh HT, Stoyanova T, Wu JC, Demirci U. PMID: 35671037.
Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 Nov; 86(Pt 3):57-68. Liu S, Alabi BR, Yin Q, Stoyanova T. PMID: 35597438.
Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 Dec; 63(12):1829-1835. Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. PMID: 35552245.
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 02 15; 3(2):100502. Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. PMID: 35243415; PMCID: PMC8861828.
Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022 Apr; 82(5):605-616. Garcia-Marques F, Liu S, Totten SM, Bermudez A, Tanimoto C, Hsu EC, Nolley R, Hembree A, Stoyanova T, Brooks JD, Pitteri SJ. PMID: 35098564; PMCID: PMC8916040.
Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods Mol Biol. 2022; 2472:221-233. Liu S, Hsu EC, Shen M, Aslan M, Stoyanova T. PMID: 35674904.
Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021 Oct 28; 7(1):141. Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S, Shen M, West M, Zhang CA, Rice MA, Brooks JD, West R, Pitteri SJ, Gyorffy B, Stoyanova T. PMID: 34711841; PMCID: PMC8553750.
Engineering Polysaccharide-Based Hydrogel Photonic Constructs: From Multiscale Detection to the Biofabrication of Living Optical Fibers. Adv Mater. 2021 Dec; 33(52):e2105361. Guimarães CF, Ahmed R, Mataji-Kojouri A, Soto F, Wang J, Liu S, Stoyanova T, Marques AP, Reis RL, Demirci U. PMID: 34617338.
Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021; 6(1):bpab014. Aslan M, Hsu EC, Liu S, Stoyanova T. PMID: 34377838; PMCID: PMC8346651.
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021 Jun 25; 11(1):13305. Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T. PMID: 34172788; PMCID: PMC8233352.
Telemedicine-Based Perioperative Management of Pheochromocytoma in a Patient With Von Hippel Lindau Disease: A Case Report. A A Pract. 2021 Jan 14; 15(1):e01378. Saksa D, Shuch B, Donahue T, Cusumano L, Yu R, Alapag C, Kamdar N. PMID: 33512909.
Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Mol Imaging Biol. 2021 10; 23(5):625-638. Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, Davidzon GA, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. PMID: 33903986; PMCID: PMC8074707.
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep. 2021 Apr 07; 11(1):7612. Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T, Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T. PMID: 33828176; PMCID: PMC8027881.
Ultra-high-frequency radio-frequency acoustic molecular imaging with saline nanodroplets in living subjects. Nat Nanotechnol. 2021 Jun; 16(6):717-724. Chen YS, Zhao Y, Beinat C, Zlitni A, Hsu EC, Chen DH, Achterberg F, Wang H, Stoyanova T, Dionne J, Gambhir SS. PMID: 33782588; PMCID: PMC8454903.
In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. Cancer Res. 2021 May 01; 81(9):2510-2521. Xie J, Rice MA, Chen Z, Cheng Y, Hsu EC, Chen M, Song G, Cui L, Zhou K, Castillo JB, Zhang CA, Shen B, Chin FT, Kunder CA, Brooks JD, Stoyanova T, Rao J. PMID: 33637565; PMCID: PMC8137584.
The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021; 9(1):73-87. Shen M, Liu S, Stoyanova T. PMID: 33816696; PMCID: PMC8012837.
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Res. 2021 Mar 15; 81(6):1583-1594. Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. PMID: 33483372; PMCID: PMC7969452.
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021 Mar; 124(5):896-900. Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T. PMID: 33288843; PMCID: PMC7921397.
